Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageMerck & Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Business segments
Q2 2026 · $9.46BThe company’s own SEC segment disclosure.
- Keytruda$4.61B49%
- Gardasil Gardasil9$542.0M6%
- Winrevair$522.0M6%
- Bridion$460.0M5%
- Pro Quad MMRII Varivax$438.0M5%
- Keytruda Qlex$395.0M4%
- Other (23)$2.50B26%
Merck & Co. (MRK) reported revenue of $16.6B in Q2 2026 (quarter ended Jun 30, 2026), up 5.1% from the same quarter a year earlier. That came with a gross margin of 74% and net loss of $1.33B. For the full year FY2025, revenue was $65.0B (+1.3% year on year) and net income $18.3B. Its largest product in Q2 2026 was Keytruda at $4.61B, 49% of the disclosed total, well ahead of Gardasil Gardasil9 at 5.7%.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - General
The closest names by size in the same industry